Lupisit M 100mg/1000mg Tablet XR is an extended-release oral medication combining Sitagliptin and Metformin, indicated for the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by increasing levels of active glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby promoting insulin release and suppressing glucagon secretion in a glucose-dependent manner. Metformin, a biguanide, primarily reduces hepatic glucose production, improves peripheral insulin sensitivity, and decreases intestinal absorption of glucose, contributing to improved glycemic control. The extended-release formulation allows for once-daily dosing, improving patient adherence and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Lupisit M is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Common adverse effects include gastrointestinal disturbances, headache, and upper respiratory tract infections. Regular monitoring of renal function and glycemic parameters is recommended to optimize therapy and ensure safety. This combination therapy offers a complementary mechanism of action to effectively manage hyperglycemia in type 2 diabetes.